Triple-negative breast cancers (TNBC) is a malignant subtype that fails to express the estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2), representing 10–20% of all breast cancer cases [1,2]. This evidence concerns the gene ESR1 and triple-negative breast carcinoma.